Lineage Cell Therapeutics (LCTX) Operating Margin (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Operating Margin of 440.17% for Q1 2026, down 708.0% year-over-year from 72.4% in Q1 2025, and down 344.21% quarter-over-quarter from 99.09% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Operating Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Operating Margin history runs 17 years deep, the most recent figure standing at 440.17% for Q1 2026.
- In Q1 2026, Operating Margin fell 708.0% year-over-year to 440.17%; the TTM figure through Mar 2026 stood at 255.14% (down 3204.0% YoY), while the FY2025 annual figure was 251.57%, down 2547.0% from the prior year.
- Operating Margin for Q1 2026 stood at 440.17%, down from 99.09% in the prior quarter.
- The five-year high for Operating Margin was 92.99% in Q2 2022, with the low at 715.37% in Q2 2025.
- The 5-year median for Operating Margin is 278.37% (2023), against an average of 291.9%.
- The sharpest annual moves came in 2022 and 2023: Operating Margin soared 168094 bps in 2022, then plunged 36297 bps in 2023.
- Lineage Cell Therapeutics' Operating Margin stood at 346.68% in 2022, then grew by 12 bps to 304.69% in 2023, then surged by 42 bps to 178.17% in 2024, then soared by 44 bps to 99.09% in 2025, then slumped by 344 bps to 440.17% in 2026.
- Business Quant data shows LCTX's Operating Margin at 440.17% in Q1 2026, 99.09% in Q4 2025, and 102.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -834.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -834.71% |
| Mar 31, 2026 | -440.17% |
| Dec 31, 2025 | -99.09% |
| Sep 30, 2025 | -102.85% |
| Jun 30, 2025 | -715.37% |
| Mar 31, 2025 | -433.09% |
| Dec 31, 2024 | -178.17% |
| Sep 30, 2024 | -101.61% |
| Jun 30, 2024 | -416.69% |
| Mar 31, 2024 | -461.29% |
| Dec 31, 2023 | -304.69% |
| Sep 30, 2023 | -538.12% |
| Jun 30, 2023 | -155.78% |
| Mar 31, 2023 | -278.37% |
| Dec 31, 2022 | -346.68% |
| Sep 30, 2022 | -175.15% |
| Jun 30, 2022 | -92.99% |
| Mar 31, 2022 | -122.13% |
| Dec 31, 2021 | -56.48% |
| Sep 30, 2021 | -301.45% |